Using a new formulation of dolcanatide to prevent colon cancer
Official title: Microsphere-based formulation of dolcanatide to prevent colon carcinogenesis
Funded at Nous Biosciences INC · NIH-10919329 · Data updated 2026-11-12
This study is testing a new oral medication called dolcanatide to help people with inflammatory bowel disease (IBD) improve their bowel function and lower their risk of developing colorectal cancer.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nous Biosciences INC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $308,650 |
| NIH project number | 1R43CA291267-01 |
| Project ID | NIH-10919329 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with inflammatory bowel disease who are at increased risk for developing colorectal cancer.
✕Less likely to help
Patients without inflammatory bowel disease or those who do not have a history of colon polyps or cancer may not benefit from this research.
What this research studies
This research investigates a novel formulation of dolcanatide, which targets the guanylyl cyclase-C (GC-C) pathway to prevent the development of colorectal cancer (CRC). The approach involves administering this formulation orally to enhance fluid secretion in the intestine and restore normal bowel function, particularly in individuals with inflammatory bowel disease (IBD) who are at higher risk for CRC. The study builds on previous findings that show a reduction in key signaling molecules in colon polyps and cancer, suggesting that restoring this signaling could help prevent cancer progression.
Why it matters
Potential benefit: If successful, this research could provide a new preventive treatment for colorectal cancer, particularly for those at high risk due to inflammatory bowel disease.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting the GC-C pathway for colorectal cancer prevention.
Where this research is happening
-
Nous Biosciences INC
Doylestown, United States Active
Researchers
- Principal investigator: Shailubhai, Kunwar — Nous Biosciences INC
- Study coordinator: Shailubhai, Kunwar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.